Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16114
|
| Title: | Clinical features and vaccination effects among children with post-acute sequelae of COVID-19 in Taiwan |
| Authors: | Hsu, YL;Chen, PC;Tsai, YF;Wei, CH;Wu, LSH;Hsieh, KS;Hsieh, MH;Lai, HC;Lin, CH;Lin, HC;Chen, CH;Chen, AC;Lin, HC;Chou, IC;Soong, WJ;Hwang, KP;Lu, HHS;Pawankar, R;Tsai, HJ;Wang, JY |
| Contributors: | Institute of Population Health Sciences |
| Abstract: | Background: Post-acute sequelae of SARS-CoV-2 infection (PASC) affects patients after recovering from acute coronavirus disease 2019 (COVID-19). This study investigates the impact of SARS-CoV-2 vaccination on PASC symptoms in children in Taiwan during the Omicron pandemic. Methods: We enrolled children under 18 years with PASC symptoms persisting for more than 4 weeks. Data collected included demographics, clinical information, vaccination status, and symptom persistence. We used logistic regression models to compare symptoms in the acute and post-COVID-19 phases and to assess the association between vaccination and these symptoms. Results: Among 500 PASC children, 292 (58.4%) were vaccinated, 282 (52.8%) were male, and the mean (SD) age was 7.6 (4.6) years. Vaccinated individuals exhibited higher odds of experiencing symptoms in the previous acute phase, such as cough (adjusted odds ratio [AOR] = 1.57; 95% confidence interval [CI]: 1.02-2.42), rhinorrhea/nasal congestion (AOR = 1.74; 95% CI: 1.13-2.67), sneezing (AOR = 1.68; 95% CI: 1.02-2.76), sputum production (AOR = 1.91; 95% CI: 1.15-3.19), headache/dizziness (AOR = 1.73; 95% CI: 1.04-2.87), and muscle soreness (AOR = 2.33; 95% CI: 1.13-4.80). In contrast, there were lower odds of experiencing abdominal pain (AOR = 0.49; 95% CI: 0.25-0.94) and diarrhea (AOR = 0.37; 95% CI: 0.17-0.78) in children who had received vaccination during the post-COVID-19 phase. Conclusions: This study revealed clinical features and vaccination effects in PASC children in Taiwan. Vaccination may reduce some gastrointestinal symptoms in the post-COVID-19 phase. |
| Date: | 2024-08-12 |
| Relation: | Vaccines. 2024 Aug 12;12(8):Article number 910. |
| Link to: | http://dx.doi.org/10.3390/vaccines12080910 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2076-393X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001307440200001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85202631764 |
| Appears in Collections: | [蔡慧如] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001307440200001.pdf | | 2446Kb | Adobe PDF | 16 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
